# **STRATEGIES FOR ACUTE PAIN MANAGEMENT** IN DENTISTRY



00th 1/75

# PRESENTED BY DAVID M H LAMBERT, DDS

The course given by David M H Lambert, DDS – a board certified oral and maxillofacial surgeon and former clinical pharmacist. This unique two hour course entails an overview of the opioid crisis as it exists today, including a review of the physiology of pain, the pharmacology of analgesics, strategies for managing acute pain, in addition to regulatory compliance issues as related to the NCBDE, closed case reviews, and tips for avoiding licensure pitfalls. This course will also serve as an ADA CERP qualified program to provide 4 CE hours credit toward MATE Act requirements for DEA permit renewal.



\$200 per person



#### CE Dojo

Nationally Approved PACE Program Provider for FAGD/MAGD credit. Approval does not imply acceptance by any regulatory authority of AGD endorsement. 4/1/2023 to 3/31/2027. Provider ID# 387596



This continuing education activity has been planned and implemented with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint efforts between Peak Compliance Services and CE DDA.







COURSE TITLE: Strategies for Acute Pain Management in Dentistry COURSE DIRECTOR: David M H Lambert, DDS PRESENTER(S): David M H Lambert, DDS AUDIENCE: RDH, Dentists CONTACT HOURS: 4.0 MEDIUM: Webinar

#### **COURSE OBJECTIVES**

- 1. Identify and discuss the evolution of the opiate crisis as we now understand it today
- 2. Identify and discuss how the COVID-19 pandemic has impacted the opiate crisis
- 3. Identify and discuss the local and national opiate epidemic statistics
- 4. Identify and discuss specific opiate epidemic statistics as they relate to Dentistry
- 5. Identify and discuss patient variables as they relate to the opiate epidemic
- 6. Review basic pain pathophysiology
- 7. Review basic pharmacokinetic concepts with emphasis on general metabolic pathways
- 8. Review opiate pharmacology and discuss individual agents with emphasis on their relative potency, efficacy, and toxicity
- 9. Review non-opiate pharmacology and discuss individual agents with emphasis on their activities, efficacy, and toxicity.
- 10. Review non-opiate multi-modal therapy and its application in Dentistry
- 11. Discuss the role of prescription opioids when employed in multi-modal therapy
- 12. Identify and discuss the importance of obtaining a proper patient history
- 13. Identify and discuss typical scenarios where dental patients may require analgesic support and how their proper management can mitigate excessive opiate prescribing
- 14. Identify and discuss inappropriate and potentially illegal opioid prescribing behaviors
- 15. Identify and discuss the profile characteristics of the malingering dental patient including diversion and factitious injury
- 17. Identify and discuss strategies to avoid triggering a pharmacy complaint to the a dental board





SERVICES



CE Dojo

Nationally Approved PACE Program Provider for FAGD/MAGD credit. Approval does not imply acceptance by any regulatory authority of AGD endorsement. 4/1/2023 to 3/31/2027. Provider ID# 387596



#### **DATES & TIMES**

Streamable ON DEMAND

## WHAT YOU NEED TO PARTICIPATE

- A desk- or laptop computer, tablet, or smartphone
- Compatible browser
- No Course Prerequisite Required
- Register for the event
- Pay your registration fee

#### **REFUNDS**

Upon registration, you will be invoiced by email to pay the event fee of \$200.00. In order to receive CE credit and certification of participation you must pay the event fee. You may receive a full refund of any monies paid upon request at any time prior to completion of the course.

### **COMMERCIAL SUPPORT**

Neither Peak Compliance Services or CE Dojo has received any commercial support for the content or production of this continuing education offering.

### **CONTACT INFORMATION**

Contact CE Dojo elearn@ce-dojo.com 252-623-3656





CE Dojo

Nationally Approved PACE Program Provider for FAGD/MAGD credit. Approval does not imply acceptance by any regulatory authority of AGD endorsement. 4/1/2023 to 3/31/2027. Provider ID# 387596